Collaborations in FemTech: How to Partner Successfully in Women’s Health

Introduction

Collaborating with a women’s health start-up or early-stage technology provider offers corporates and investors a unique opportunity to drive innovation in an area of growing social and economic importance. For FemTech innovators, collaborations provide access to funding, clinical and regulatory expertise, and distribution channels – helping validate solutions, accelerate scale-up, and build stakeholder trust.

This article considers potential structures for formal collaborations between corporates or investors and start-ups in FemTech, and examines key considerations and risks to navigate for success.

 

Why collaborate?

Before looking at the mechanics of collaboration, it is worth considering why collaborations are so attractive in the sector:

• Faster product development – Corporates access specialist capability and reduce development risk; innovators gain clinical input and operational support to move from prototype to scalable product faster.
• Route to market – Partners combine capital, regulatory knowhow and commercial channels to accelerate adoption, shortening time‑to‑revenue and building credibility with purchasers and patients.
• ESG – Investing in women’s health supports social-impact and diversity objectives; innovators may benefit from impact‑linked capital and procurement pathways.

 

What structures can be used to collaborate?

Parties seeking to collaborate in FemTech have a range of structures available. Three common options, each with different characteristics, advantages, and challenges, are corporate joint ventures, strategic investments, and contractual partnerships.

Corporate Joint Ventures

A corporate joint venture involves creating a separate legal entity owned and governed by the collaborating parties, with each contributing assets, capital, or expertise, and sharing in risks and rewards.

Joint ventures suit ambitious, long-term collaborations on specific projects (eg co-developing a medical device platform or entering a new territory). The separate entity provides clear governance, decision-making, and profit-sharing structures, and can hold regulatory authorisations, employ staff, and contract with third parties.

However, joint ventures bring complexity. Governance must address decision-making (including deadlock resolution), funding obligations, and party roles. Exit mechanisms require particular attention-consider what happens if one party wishes to withdraw or the venture fails. For FemTech, determine what should happen to regulatory authorisations (including CE/UKCA markings) and proprietary IP developed by the JV.

Strategic Investment

An alternative is for a corporate or investor to take an equity stake in an early-stage company-whether minority, majority, or full acquisition. This model is common where a corporate wishes to gain FemTech exposure without joint venture complexity.

The investor typically gains financial upside if the investee succeeds, alongside governance rights (board representation, information rights, consent rights over significant decisions). The investee gains capital and a strategic partner with resources and expertise to support growth.

Key structuring considerations include valuation (challenging for early-stage companies with limited revenue), anti-dilution protections, founder lock-in arrangements, and exit terms.

Contractual Partnerships

Rather than creating a joint entity or taking equity, parties can collaborate through commercial agreements at arm’s length. This flexible model is widely used in FemTech, offering distinct legal advantages while requiring careful risk management.

Contractual partnerships include technology licensing, joint R&D, and distribution agreements. Each party retains corporate independence, with liability generally confined to the contract itself. Parties also maintain control over their regulatory compliance, IP portfolios, and strategic direction-important when working with rapidly evolving FemTech products.

The main risks flow from the arm’s length relationship itself. Without shared ownership, interests may diverge, and either party can exit when the contract ends. Key issues to address upfront include IP ownership in jointly developed technology, data access and usage rights, and remedies for underperformance. Consider whether exclusivity or minimum performance obligations are needed to protect investment.

 

What are the key risks and challenges in FemTech collaborations?

The value of data

Many FemTech providers are early‑stage companies, operating in start‑up mode with innovative products but relatively immature governance structures. In this environment, data sets often represent the core asset, particularly because it is commercially valuable to partners, acquirers or investors in digital health, pharmaceuticals, insurance, and consumer wellness sectors. As FemTech companies enter fundraising, joint ventures or M&A processes, the ability of a purchaser, partner or investor to lawfully use the inherited data becomes one of the main determinants of valuation. If personal data has been collected without a valid lawful basis, or for purposes which are inconsistent with those set out in privacy notices, it may be unusable, forcing acquirers or investors to ring‑fence or even delete it. Weak data governance can therefore become a material deal risk, reducing commercial value or triggering enhanced warranties and indemnities in the sale agreement. A well‑documented data protection programme can safeguard the value of the most important asset many FemTech companies hold.

Intellectual Property

IP is often the most valuable asset in a FemTech collaboration. Whether the partnership involves a diagnostic algorithm, wearable tracker, or digital therapeutics platform, the question of who owns the resulting IP – and on what terms it may be used – is fundamental.

• Ownership: The critical distinction is between background IP (what each party brings to the collaboration) and foreground IP (what is created during it). Background IP should be clearly identified, with each party typically retaining ownership but granting licences for collaboration purposes. For foreground IP, parties must agree whether it will be owned solely, jointly, or assigned to a JV entity. Joint ownership can create difficulties when it comes to actual usage/exploitation, enforcement, licensing or transferring the IP; sole ownership with a licence back is generally preferable.
  
  
• Licensing: Key issues include identifying and defining the licensed IP, territorial scope, exclusivity, field of use, duration (including term and termination or if perpetual), sub-licensing rights, whether transferable, and commercial terms (royalties, milestones, minimum performance). In FemTech, licensing must also address regulatory considerations-the authorisation holder may need ongoing access to underlying technical documentation and IP throughout the product lifecycle.
  
  
• Protection: Collaboration agreements should include confidentiality obligations for proprietary information including confidential and technical information and know-how, non-compete and non-solicitation provisions where appropriate, and clear enforcement mechanisms including audit rights and remedies for breach. Consideration should also be given to who will be responsible for registering and maintaining new and existing IP rights and for defending these rights.

• FemTech-specific considerations: Software, algorithms, and training data are central to many FemTech products, particularly software as a medical device-ownership should be expressly addressed. Data generated by FemTech products (menstrual cycles, fertility metrics, pregnancy monitoring) raises distinct questions about ownership, use for product improvement, research, and AI training. Regulatory dossiers and clinical data also represent significant value-agree whether either party may rely on this data for its own regulatory submissions.

Competition and Antitrust

Collaborations between competitors or parties with significant market positions may trigger merger control filings or raise anti-competitive concerns. Even joint ventures and certain strategic investments can require notification to competition authorities. Parties should be mindful of information sharing throughout-particularly pricing, customer data, and commercial strategies. Appropriate confidentiality protocols and clean team arrangements may be necessary.

AI and Algorithm Transparency

Many FemTech products rely on AI and machine learning-for example, fertility prediction algorithms or diagnostic tools. Parties should address ownership of training data and resulting models, and consider how evolving regulatory requirements (such as the EU AI Act) will affect their products. Explainability and algorithm auditing may become contractual obligations, particularly for high-risk AI systems. Collaboration agreements should allocate responsibility for regulatory compliance and liability for AI-driven decisions.

Product Liability and Insurance

FemTech products-particularly medical devices-carry inherent product liability risks. Collaboration agreements should clearly allocate liability for defects in design, manufacture, or instructions for use. Insurance is a key negotiating point: agree minimum coverage levels, named insured status, and notification obligations. For multi-jurisdictional distribution, consider local liability regimes and insurance requirements.

Regulatory Pathway Alignment

Parties should ensure product development timelines align with regulatory requirements. Clinical evidence generation, notified body capacity for CE marking, and FDA submission timelines can all affect time-to-market. Misaligned expectations about regulatory pathways are a common source of friction. Agreements should address responsibility for regulatory strategy, who leads interactions with authorities, and how delays will be managed.

Cultural and Operational Integration

Collaborations between corporates and start-ups often involve bridging different organisational cultures-start-ups operate with agility; corporates bring structured governance. These differences can create friction if not anticipated. Practical considerations include decision-making processes, reporting requirements, and how regulatory and quality obligations will be met. Regular review meetings and clear escalation paths help manage the relationship.

Gainshare and Painshare

For a collaboration to succeed, both parties should share in gains and pain. While splits need not be equal, transparent mechanisms for allocating profit, loss, and risk create genuine alignment. Consider how revenue, costs, and risks will be allocated across scenarios-including underperformance. Where one party makes significant upfront investment, compensatory termination payments may be appropriate.

 

Cross-Border Collaborations: Specific Risks and Considerations

Many FemTech collaborations involve parties in different jurisdictions, or contemplate development and commercialisation across multiple markets, bringing additional complexity.

 

Regulatory Divergence

The regulatory landscape for medical devices and digital health products varies significantly between jurisdictions. This subject is explored in further detail in The Legal Landscape of FemTech article.

This divergence has practical implications. Products may need separate certification for EU and UK markets, with distinct technical documentation, authorised representatives, and post-market surveillance. Agreements should address regulatory responsibilities, dual certification costs, and management of changing requirements.

The US position differs-FDA regulates medical devices with separate pre-market clearance requirements. Transatlantic collaborations must plan for multiple regulatory pathways and associated costs.

 

Data Protection and Cross-Border Data Flows

FemTech products typically collect and process health data, classified as special category data under UK and EU GDPR. Requirements for processing such data are stringent, and penalties for non-compliance severe. This is explored further in the Privacy and Data Security in FemTech article.

Cross-border collaborations must address how personal data will be shared and whether transfers outside the UK or EEA are necessary. International transfers require appropriate safeguards – adequacy decisions, standard contractual clauses (SCCs), or binding corporate rules – to ensure equivalent protection in the destination country.

Given the sensitivity of FemTech data, parties should consider reputational risks. A data breach involving fertility or pregnancy information could cause significant harm to individuals and serious damage to brands and commercial relationships.

 

Governing Law and Dispute Resolution

Cross-border collaborations raise questions of governing law and dispute resolution. Parties must agree which jurisdiction’s laws will govern and where disputes will be resolved.

Choice of law matters-different jurisdictions have different rules on contract interpretation, limitation of liability, and enforceability of restrictive covenants.

Arbitration offers advantages in cross-border disputes-neutrality, confidentiality, and enforceability under the New York Convention. Agree the seat, applicable rules, and language of proceedings.

 

Structuring for Success: Practical Guidance

Drawing together the themes above, we offer the following practical guidance for parties entering FemTech collaborations:

1. Conduct thorough due diligence. Understand your counterparty’s IP portfolio, regulatory status, data governance, and financial position. Identify risks early.
2. Align on objectives early. Ensure that both parties have a shared understanding of the collaboration’s goals, timeline, and measures of success. Misaligned expectations are a common cause of partnership failure.
3. Document clearly. Capture key terms in legally binding agreements. Avoid prolonged reliance on MOUs or letters of intent, which may create uncertainty about rights and obligations.
4. Plan for change. Collaborations evolve. Build in mechanisms to address changes in scope, regulatory requirements, or market conditions.
5. Address termination and exit at the outset. Define what happens to IP, data, and regulatory authorisations if the collaboration ends, including ongoing product support and liability allocation.
6. Engage advisers early. FemTech collaborations sit at the intersection of life sciences regulation, data protection, intellectual property, and corporate structuring. Multidisciplinary advice is essential.

 

Conclusion

Collaboration offers significant opportunities for corporates, investors, and start-ups seeking to make an impact in FemTech. Whether through a joint venture, strategic investment, or contractual partnership, well-structured collaborations can unlock innovation, accelerate market access, and deliver better outcomes for women’s health.

Unlike traditional customer/supplier arrangements, strategic partnerships require a genuinely collaborative approach to contract drafting. It is counterproductive to impose standard terms. Instead, work together to create bespoke, balanced terms reflecting the shared nature of the venture-particularly important in corporate/start-up collaborations where power imbalances may exist.

The sensitivity of this sector – dealing with intimate health data and regulated medical products – demands careful attention to legal structure, IP rights, and cross-border risks.

Future articles in this series will examine data privacy in FemTech, investment considerations, and the emerging role of AI. Stakeholders contemplating collaborations are encouraged to seek early, specialist advice to navigate the complex legal landscape.

This article is part of the FemTech Now series. Access the hub here.